26 to 28 April 2018
The AGAH’s 27th annual meeting will focus on how to predict as well as on how to prevent adverse drug reactions in early phase drug development. The major target organ systems will be addressed: liver, kidney, CNS, cardiac function. Further sessions will be dedicated to local tolerance and immunotoxicity.
They will look into how animal models and in vitro data may help to estimate risk regarding human administration. How can kidney and liver function best be monitored in the settings of early phase trials? What do we need to know to assess potential CNS adverse drug reactions early on? What are the pathophysiological mechanisms leading to potential cardiac toxicity? What are the guidelines on non-clinical local tolerance testing? How to monitor immunotoxicity in novel immunological therapies? There will be ample opportunity to discuss these and additional questions with expert speakers, regulators and ethic committees members as well as colleagues from pharmaceutical industry, CRO and academia.
The meeting starts with a one-day pre-conference workshop about basic terms and key concepts of pharmacovigilance with a strong focus on early phase drug development. This workshop offers an excellent preparation for the annual meeting for those who are not yet experts in the field.
Follow this link to see the full programme and to register.
AGAH e. V. is a founding member of EUFEMED.